Adam E. Logal
Net Worth
Last updated:
What is Adam E. Logal net worth?
The estimated net worth of Mr. Adam E. Logal is at least $15,411,980 as of 9 May 2019. He owns shares worth $237,616 as insider, has earned $1,854,364 from insider trading and has received compensation worth at least $13,320,000 in OPKO Health, Inc..
What is the salary of Adam E. Logal?
Mr. Adam E. Logal salary is $1,110,000 per year as Senior Vice President & Chief Financial Officer in OPKO Health, Inc..
How old is Adam E. Logal?
Mr. Adam E. Logal is 47 years old, born in 1978.
What stocks does Adam E. Logal currently own?
As insider, Mr. Adam E. Logal owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| OPKO Health, Inc. (OPK) | Senior Vice President & Chief Financial Officer | 176,012 | $1.35 | $237,616 |
What does OPKO Health, Inc. do?
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Adam E. Logal insider trading
OPKO Health, Inc.
Mr. Adam E. Logal has made 3 insider trades between 2013-2019, according to the Form 4 filled with the SEC. Most recently he purchased 3,250 units of OPK stock on 9 May 2019.
The largest trade he's ever made was exercising 264,207 units of OPK stock on 13 Mar 2017. As of 9 May 2019 he still owns at least 176,012 units of OPK stock.
OPKO Health key executives
OPKO Health, Inc. executives and other stock owners filed with the SEC:
- Dr. Jane H. Hsiao Ph.D., MBA (78) Vice Chairman & Chief Technical Officer
- Dr. Jon R. Cohen (70) Senior Vice President & Director
- Dr. Phillip Frost Ph.D. (89) Chairman & Chief Executive Officer
- Mr. Adam E. Logal (47) Senior Vice President & Chief Financial Officer
- Mr. Steven D. Rubin (65) Executive Vice President of Admin. & Director